Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: The majority of studies relating amyloid pathology with brain volumes have been cross‐sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer's disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss. Methods: We evaluated whether an abnormal level of cerebrospinal fluid beta‐amyloid (CSF Aβ) and APOE ɛ4 carrier status were independently associated with greater hippocampal volume loss over 1 year. We then assessed whether APOE ɛ4 status and CSF Aβ acted synergistically, testing the significance of an interaction term in the regression analysis. We included 297 participants: 77 cognitively normal, 144 with mild cognitive impairment (MCI), and 76 with Alzheimer's disease. Results: An abnormal CSF Aβ level was found to be associated with greater hippocampal volume loss over 1 year in each group. APOE ɛ4 was associated with hippocampal volume loss only in the cognitively normal and MCI groups. APOE ɛ4 carriers with abnormal CSF Aβ in the MCI group acted synergistically to produce disproportionately greater volume loss than noncarriers. Conclusion: Baseline CSF Aβ predicts progression of hippocampal volume loss. APOE ɛ4 carrier status amplifies the degree of neurodegeneration in MCI. Understanding the effect of interactions between genetic risk and amyloid pathology will be important in clinical trials and our understanding of the disease process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“First, the ADNI was designed to mimic a trial population, so participants were more educated, more Caucasian, and had fewer comorbidities, as compared with a community-based cohort [43].”
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“We excluded 33 subjects who carried a minimum of one APOE 3 2 allele to avoid confounding the analysis because APOE 3 2 is believed to be protective against development of AD and associated with slower rates of hippocampal atrophy [31,32].”
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168 · cited 1×
“Indeed, APOE 3 4 has been found to be associated with an inability to repair synaptic damage; more rapid promotion of other neurotoxic species, such as tau; susceptibility to oxidative stress; and promotion of inflammatory cascades [17], beyond simply increasing levels of brain amyloid.”
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“There are a few studies that have found similar correlations between cerebrospinal fluid (CSF) Ab, an indirect measure of cerebral amyloid deposition [6,7], and hippocampal atrophy [8,9].”
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 3×
“Early onwhen subjects demonstrate normal cognition, the predominant effect ofAPOE 34 seems to be to increase brain amyloid deposition, as reported by numerous previous studies [15–18].”
Self-citationEpisodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684
Self-citationSchuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Weiner, M. W., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awp007 · Cited by 679
Self-citation
Cited by
Jia, J., Zhao, T., Liu, Z., Liang, Y., Li, F., Li, Y., Liu, W., Li, F., Shi, S., Zhou, C., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072691 · Cited by 252
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220
Self-citationCavedo, E., Lista, S., Rojkova, K., Chiesa, P. A., Houot, M., Brueggen, K., Blautzik, J., Bokde, A. L. W., Dubois, B., Barkhof, F., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.048 · Cited by 40
“…such as the subiculum (Burggren et al., 2008, Suthana et al., 2010) and CA1 subfield (Kerchner et al., 2014) of the hippocampus (Donix et al., 2010a, Chiang et al., 2011, O'Dwyer et al., 2012, Taylor et al., 2014), although contrasting results were published as well (Jack et al., 1998, Du et al.,…”
ResultLu, L., Kotowska, A. M., Kern, S., Fang, M., Rudd, T. R., Alexander, M. R., Scurr, D. J., & Zhu, Z. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01201 · Cited by 15
Metadata
- Authors
- Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., Jagust, W. J., Harvey, D. J., Beckett, L. A., Gamst, A., Aisen, P. S., Petersen, R. C., & Weiner, M. W.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-09
- Volume
- 7
- Issue
- 5
- Pages
- 514-520
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2158008198
- Cited by
- 31
- References
- 17
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. https://app.cochat.ai/papers/10.1016/j.jalz.2010.12.010
- The paper
- Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., Jagust, W. J., Harvey, D. J., Beckett, L. A., Gamst, A., Aisen, P. S., Petersen, R. C., & Weiner, M. W. (2011). Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2010.12.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.